Latest NewsJun 18, 2025HiFiBiO Therapeutics to Present Preclinical Data of Three Leading I&I Programs at the 2025 Annual Meeting of the Federation of Clinical Immunology SocietiesAll Filter By: Year20252024202320222021202020192018201720162015Aug 15, 2022HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid TumorsApr 27, 2022HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB200301 at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingApr 18, 2022HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatmentApr 18, 2022Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumorsApr 18, 2022Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization< 1 … 4 5 6 7 8 … 17 >
